Global Human Papillomavirus (HPV) Vaccine Market to Reach About USD 13.96 Billion by 2032, Driven by the Growing Prevalence of HPV-Related Diseases and Cancers

The market for human papillomavirus (HPV) vaccine is being aided by the growing cases of HPV-related cancers and diseases. The introduction of various favourable government initiatives to reduce the burden of cancer and other diseases caused by HPV types is also surging the demand for human papillomavirus (HPV) vaccines. The increasing launches of gender-neutral human papillomavirus (HPV) vaccines are also bolstering the market growth. Furthermore, leading companies are increasingly initiating various research and development (R&D) activities to manufacture low-cost human papillomavirus (HPV) vaccines against cervical cancers. Hence, the availability of low-cost human papillomavirus (HPV) vaccines is expected to surge its demand in middle-and-low-income countries.

The emerging evidence regarding the efficacy of single-dose human papillomavirus (HPV) vaccines is driving the market. In addition, single-dose vaccines are cost-effective, less resource initiative, and easy to administer, due to which they are increasingly preferred. With the increasing focus for eliminating cervical cancers by introducing various programmes such as the Cervical Cancer Elimination Initiative by the WHO, the utilisation of human papillomavirus (HPV) vaccines is rising.

Merck & Co., Inc. (NYSE: MRK), one of the leading companies in the market, announced in June 2020 that an expanded indication for GARDASIL®9, a recombinant human papillomavirus 9-valent vaccine, has been approved by the Food and Drug Administration (FDA) of the United States. The approval for the indication may be contingent upon the description and verification of clinical benefit in a confirmatory trial. The approval of this vaccine for the prevention of HPV-related oropharyngeal and other neck and head cancers marks a significant step in the company’s mission to reduce the prevalence of HPV-related cancers.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis by Type, Distribution Channel, Indication, Disease, and Region:

• The market, on the basis of type, can be divided into bivalent and polyvalent.

• The major distribution channels for human papillomavirus (HPV) vaccine include hospital and retail pharmacies and government suppliers, among others.

• Based on indication, the market can be divided into genital warts and HPV associated cancer.

• By disease, the market is classified into systemic human papillomavirus vaccine and localised human papillomavirus vaccine.

• The regional markets for human papillomavirus (HPV) vaccine include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Key Findings of the Report:

• The rising awareness regarding the prevalence of human papillomavirus (HPV) is propelling the market for human papillomavirus (HPV) vaccine.

• The market is being aided by the robust development of healthcare infrastructure and the growing prevalence of sexually transmitted infections.

• The growing cases of human papillomavirus diseases are augmenting the market for human papillomavirus (HPV) vaccine.

• The increasing incidences of HPV-related malignancies in the anal, oropharynx, and genital areas, among others, are invigorating the market growth of human papillomavirus (HPV) vaccine.

Key Offerings of the Report:

• The EMR report gives an overview of the global market for human papillomavirus (HPV) vaccine for the periods (2018-2023) and (2024-2032).

• The report also offers the historical (2018-2023) and forecast (2024-2032) markets for the types, distribution channels, indications, diseases, and major regions of human papillomavirus (HPV) vaccine.

• It assesses the regional price trends for the (2018-2023) and (2024-2032) periods.

• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with an assessment of the SWOT and Porter’s Five Forces models.

The major players in the global human papillomavirus (HPV) vaccine market are Merck & Co., Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Inc., Serum Institute of India Pvt. Ltd., and Bavarian Nordic A/S, among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: sales@expertmarketresearch.com
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.